TrialJapanese journal of clinical oncology2025

First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.

Hsiao-Jen Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.